| octreotide acetate / Generic mfg. |
| Completed | 4 | 45 | | 0.9%saline muscular injection monthly ;20mg long-acting octreotide muscular injection mon ;40mg long-acting octreotide muscular injection mon | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, none | portal hypertension | | | | |
ChiCTR-TRC-14004384: Long-acting Octreotide Prevents Variceal Rebleeding in Patients with Portal Hypertension |
|
|
| Completed | 4 | 75 | | 0.9%saline muscular injection monthly ;20mg long-acting octreotide muscular injection monthly ;40mg long-acting octreotide muscular injection monthly | Shanghai Sixth People's Hospital; Level of the institution：, self-funding | liver cirrosis, portal hypertension | | | | |
| Ongoing | 4 | 30 | Europe | Octreotide, SMS995, Sandostatine 0,1 mg/ml, Sandostatine LAR 20 mg, Sandostatine 0,1 mg/ml, Sandostatine LAR 20 mg | UZ LEUVEN | Dumping Syndrome is a condition characterized by weakness, dizziness, flushing and warmth, nausea and palpitation immediately or shortly after eating and produced by abnormally rapid emptying of the stomach in persons who have had part of the stomach removed or in hypersensitive or neurotic individuals | | | | |
2009-017849-57: Somatostatin analogues as a volume reducing treatment of polycystic livers |
|
|
| Ongoing | 4 | 50 | Europe | Sandostatin LAR, Somatuline Autosolution, unknown, | Radboud University Nijmegen Medical Centre | Polycystic liver disease, due to isolated polycystic liver disease or polycystic kidney disease. | | | | |
| Ongoing | 4 | 100 | Europe | Somatuline Autogel, Sandostatin LAR, Dostinex, Somavert, Somatuline Autogel, Sandostatin LAR, Dostinex, Somavert | Österreichisches Akromegalie Register, Österreichisches Akromegalieregister | Acromegaly | | | | |
2014-003856-30: Trial for patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR. |
|
|
| Ongoing | 4 | 50 | Europe | SANDOSTATIN LAR, Injection, Sandostatine Long Acting Repeatable (LAR) 10, 20, 30 mg | Cliniques Universitaires Saint Luc, Cliniques Universitaires Saint Luc, Novartis pharma SA/NV | The primary objective is to observe the change from baseline in the incidence of diarrhea and flushing in correlation to the serum octreotide level, independently of the dose variations of octreotide LAR., To observe the change from baseline in the incidence of diarrhea and flushing in relation to the serum octreotide level (level in the blood) independently of the dose variations of octreotide LAR., Diseases [C] - Cancer [C04] | | | | |
NCT03289741: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide |
|
|
| Completed | 4 | 53 | US | Octreotide, LAR Lanreotide, Questionnaires | Memorial Sloan Kettering Cancer Center | Neuroendocrine Tumors | 04/23 | 04/23 | | |
| Recruiting | 4 | 100 | | Long acting octreotide 20mg/30mg injection was given every 28 days for 12 months ;Follow-up observation | Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Self-funded | Neuroendocrine Tumors | | | | |
